A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The main objective is to determine the feasibility of dasiglucagon in a bi-hormonal reactive
closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients
with diabetes mellitus type 1. Safety parameters and pharmacodynamics are compared between
Dasiglucagon and GlucaGen®.
This study is a single-center, double-blinded, randomized, cross over trial in 12 subjects.
The subjects will be randomized to receive either dasiglucagon or GlucaGen® for the first
three day study period and switch to the alternate treatment after a wash-out treatment.